|
RSV Vaccine for Infants and Children
Application
Vaccine for Respiratory Syncytial Virus (RSV) in infants and children.
Key Benefits
A novel vaccine targeting both the F and G proteins of the respiratory syncytial virus (RSV), including its variants.
Preliminary data in in mice show the vaccine induced the production of antibodies associated with preventing disease.
Potential to...
Published: 2/13/2025
Updated: 8/5/2024
Inventor(s): Larry Anderson, Binh Ha, Heying Sun
|
|
Therapeutic to Treat Age-Dependent Idiopathic Pulmonary Fibrosis
Application
Therapeutic for treating age-associated lung fibrosis.
Key Benefits
Tecfidera (dimethyl fumarate - DMF) is an FDA approved therapy to treat multiple sclerosis via oral administration.
A novel formulation for inhaled delivery demonstrated efficacy for a new indication: Idiopathic Pulmonary Fibrosis (IPF), where it promotes the reversal...
Published: 2/13/2025
Updated: 4/7/2023
Inventor(s): Louise Hecker, Kosuke Kato, Priyadarshini Muralidharan, Heidi Mansour
|
|
Improving Pediatric Asthma Management for Urban Families
Application
Home-based family psychoeducational intervention for low-income children with persistent asthma.
Key Benefits
Medical and psychosocial needs of patients and family members can be addressed simultaneously.
Significantly improved asthma management and caregiver stress in randomized controlled clinical trial.
Market Summary
Asthma...
Published: 2/13/2025
Updated: 4/7/2023
Inventor(s): Marianne Celano, Lisa Kobrynski, Chanda Holsey
|
|
Mobile Application for COPD Patients
Application
Mobile application for teaching breathing techniques to patients with chronic obstructive pulmonary disease (COPD).
Key Benefits
Personalized coaching program.
Tracks and saves lung performance.
Adapts training program to patient’s lung performance.
Can be done from the comfort of the patient’s home.
Market Summary
Chronic...
Published: 2/13/2025
Updated: 4/7/2023
Inventor(s): Weihua Zhang
|
|
CFTR Modulators for Treating Rare Forms of Cystic Fibrosis
Application
Small molecules to treat cystic fibrosis and other pulmonary diseases.
Key Benefits
Rescue rare variants of CFTR gene.
Serve as PDE4 inhibitors with strong anti-inflammatory effects.
Market Summary
Cystic fibrosis (CF) is a progressive, genetic disorder that arises from mutations in the cystic fibrosis transmembrane conductance...
Published: 2/13/2025
Updated: 4/7/2023
Inventor(s): Eric J. Sorscher, Jeong Hong, Haian Fu, Yuhong Du, Huw Davies, Andras Rab, Candela Manfredi, Xun Yang, Zhi Ren
|
|
Alexidine and Analogs to Treat Lung Cancer
Application
Small molecule therapeutic specifically targeting invasive cancer cells for treatment of lung cancer.
Key Benefits
Inhibits cancer cell invasion.
Utilizes a novel mechanism of action.
Market Summary
One of the main barriers in developing new treatment strategies is the vast diversity between and within cancers. The cells within...
Published: 2/13/2025
Updated: 4/7/2023
Inventor(s): Adam Marcus, Jessica Konen, Rachel Commander, Jamie Arnst, Thota Ganesh
|
|
Plasmid for Respiratory Syncytial Virus (RSV) Vaccine Development & Research
Applications
Bacterial artificial chromosome (BAC) plasmid containing the antigenomic sequence A2-BAG-BAF derived from multiple strains of RSV.
Key Benefits
Viral DNA is contained in a BAC, allowing for efficient mutagenesis and recombineering of viral DNA.
BAC is stable and can be used for cloning in common bacteria types like E. coli.
Provides...
Published: 2/13/2025
Updated: 4/7/2023
Inventor(s): Martin Moore, Anne Hotard (Lopez-Ona)
|
|
GeneRegs: Nanoparticles for Treatment of Severe Asthma
Application
Gold nanoparticles coated with enzyme which specifically targets and degrades asthma-associated inflammation molecules.
Key Benefits
Specifically suppresses asthma associated inflammation.
Easy self-administration by inhalation.
Market Summary
Asthma is defined as a chronic inflammatory lung disease with significant worldwide morbidity....
Published: 2/13/2025
Updated: 4/7/2023
Inventor(s): Khalid Salaita, Cherry Wongtrakool, Kornelia Galior
|
|
Respiratory Syncytial Virus (RSV) A2 Expressing Firefly Luciferase
Application
Recombinant RSV strain expressing firefly luciferase and the F & G genes from clinical strain A2001/2-20 for research and development of vaccines.
Key Benefits
F & G proteins included in this strain show different behavior than those of the typical A2 strain proteins.
May be adapted in a variety of assays, enabling the identification...
Published: 2/13/2025
Updated: 4/7/2023
Inventor(s): Martin Moore, Christopher Stobart
|
|
Recombinant RSV Strains Expressing Renilla Luciferase and G & F Proteins
Application
Recombinant respiratory syncytial virus (RSV) strains expressing the G and F Proteins from RSV strains as well as renilla luciferase for use in drug and vaccine screening.
Key Benefits
Provides new and needed tool for screening potential RSV therapies, ensuring they are broadly effective against multiple, distinct strains of the virus....
Published: 2/13/2025
Updated: 4/7/2023
Inventor(s): Martin Moore, Jia Meng
|
